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Table 1. Univariable Hazard Ratios of CKD With 95% Conﬁdence
Intervals
Factor
No CKD
(n  1314)
CKD
(n  279)
Hazard Ratio
(95% CI)
Age (years)
0–10 176 (95) 10 (5) 0.2 (0.1–0.5)
11–17 81 (81) 19 (19) 0.9 (0.6–1.5)
18–40 474 (82) 106 (18) 0.9 (0.7–1.2)
>40 583 (80) 144 (20) 1.0
Sex
Female 626 (81) 143 (19) 1.0
Male 688 (83) 136 (17) 0.9 (0.7–1.1)
Donor
Matched sibling 537 (82) 117 (18) 1.0
Non-sibling
relative
79 (77) 24 (23) 1.4 (0.9–2.2)
Unrelated 425 (77) 128 (23) 1.4 (1.1–1.8)
Autologous or id
twin
273 (96) 10 (4) 0.2 (0.1–0.4)
Transplant type
Non-myeloablative 56 (77) 17 (23) 1.0
Myeloablative 1258 (83) 262 (17) 1.4 (0.9–2.3)
TBI Conditioning
No 569 (87) 83 (13) 1.0
Yes 745 (79) 196 (21) 1.7 (1.3–2.2)
Cyclosporine
prophylaxis
No 79 (89) 10 (11) 1.0
Yes 990 (79) 261 (21) 1.9 (1.0–3.5)
Missing 245 (97) 8 (3) 0.3 (0.1–0.7)
Bilirubin in first 100
days
Median (range)
Average 1.1 (0.2–16.5) 1.7 (0.2–16.4) 1.2 (1.16–1.25)
Maximum 2.4 (0.2–41.2) 4.0 (0.3–56.8) 1.07 (1.05–1.08)
Acute GVHD grade
0 143 (88) 19 (12) 1.0
I 64 (94) 4 (6) 0.5 (0.2–1.5)
II 576 (83) 115 (17) 1.5 (0.9–2.4)
III or IV 249 (66) 127 (34) 3.7 (2.3–5.9)
Auto or twin 273 (96) 10 (4) 0.3 (0.1–0.7)
Chronic GVHD
No 369 (73) 136 (27) 1.0
Yes 643 (84) 123 (16) 1.8 (1.4–2.3)
Auto or twin
transplant
273 (96) 10 (4) 0.2 (0.1–0.4)
Missing 29 (74) 10 (26) 2.3 (1.2–4.3)
ARF before day 60
No 1050 (85) 187 (15) 1.0
Yes 264 (74) 92 (26) 1.8 (1.4–2.4)
Diagnosis
ALL 151 (86) 24 (14) NS/data not
shown
ANL 236 (79) 64 (21) NS
CML 383 (79) 99 (21) NS
MDS 147 (77) 44 (23) NS
MM 62 (83) 13 (17) NS
NHL 95 (87) 14 (13) NS
Other 240 (92) 21 (8) NS
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JC VIRUS REACTIVATION IN HEMORRHAGIC CYSTITIS COMPLICATING
BONE MARROW TRANSPLANTATION PATIENTS
Manna, P.1, Grantham, K.1, Reddy, S.1, Nath, R.2 1Department of
Molecular Diagnostic Research, ViraCor Laboratories, Lee’s Summit,
MO; 2St. Joseph Regional Medical Center, Patterson, NJ.
Background: Late-onset hemorrhagic cystitis (HC) is a well-
known severe complication of bone marrow transplantation
(BMT). Protracted postengraftment HC is associated with graft-
versus-host disease and viral infections, caused mainly by BK virus
(BKV) or adenoviruses (AdV). However, the roles of other closely
related polyomaviruses, such as JCV and SV40, are not known.
Here we investigated whether these polyomaviruses can also be
detected in patients affected by postengraftment HC. Methods:
We screened 47 blood specimens obtained from 27 BMT patients
affected by HC to diagnose for JCV, BKV, and adenovirus infec-
tions. We also screened for herpesviruses, such as EBV and CMV,
on these patients to determine their roles in clinical complications
of HC. Results: We have developed quantitative real-time PCR
assays that are highly sensitive and speciﬁc for each virus. Our
results showed that although the majority of the patients (15 of 27
patients; 55%) with HC were diagnosed to have BK infections;
JCV was detected in 2 patients (7%). BKV viruria was also detected
in these 2 JCV-positive patients affected by postengraftment HC.
Adenoviruses, the other pathogens that also cause HC, were de-
tected in 2 patients (7%). One patient (3%) had both BKV and
JCV coinfections. Additionally, 8 patients (30%) were simulta-
neously infected with herpesviruses and polyomaviruses, compared
with herpesviruses alone (4 patients or 15%). SV40 was not de-
tected in any of these patients. Conclusions: A large proportion of
the BMT patients suffering from HC are diagnosed to have poly-
omaviruses. The detection of JC virus suggests that this virus may
be involved in the HC in BMT patients. Polyomaviruses share
substantial structural and genomic sequence homologies; however,
their clinical manifestations differ signiﬁcantly. These viruses es-
tablish subclinical and persistent infections and share the capacity
for reactivation from latency in their host under immunosuppres-
sion. JCV establishes latency mainly in the kidney, and its reacti-
vation results in the development of progressive multifocal leu-
koencephalopathy. BKV causes infection in the kidney and the
urinary tract, and its activation causes a number of disorders,
including nephropathy and hemorrhagic cystitis. Further clinical
studies are needed to assess the role of coinfections in BMT
patients affected by HC.
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Background: Candida infections account for 70%-80% of inva-
sive fungal infections and are among the most common nosocomial
bloodstream infections in BMT patients. Hence rapid identiﬁca-
tion of these Candida species may facilitate optimal antifungal
therapy and patient management. However, current biochemical
and phenotypic methods performed on isolated yeast colonies may
require up to a week. Here we report a rapid and sensitive geno-
typic method for identifying 6 Candida species: the 4 most com-
monly encountered species (C. albicans, C. glabrata, C. parapsilosis,
and C. tropicalis) and 2 inherently antifungal-resistant species (C.
krusei and C. lusitaniae). Identiﬁcation of these Candida species was
achieved by a single real-time PCR reaction with a novel molecular
beacon ﬂuorescent-probe and melting curve analysis. Methods:
We have designed a primer set for a unique region of the multi-
copy 18s rRNA gene. This primer set can amplify all 6 Candida
species in real time PCR using a nonspeciﬁc dye, SYBR Green. We
have designed a novel molecular beacon probe that hybridizes to
the internal sequences and exploits the slight sequence variations
between the species. Thus each Candida species may be discrimi-
nated by melting temperature (Tm) analysis. The performance of
this newly developed assay was evaluated in clinical blood speci-
mens that were spiked with several different dilutions of each
Candida species. Results: We have developed a real-time quanti-
tative PCR assay based on real-time ﬂuorimetric quantiﬁcation of
PCR products and evaluated its clinical diagnostic utility in inva-
sive candidiasis. Results indicate that our newly developed assay
can detect and quantify as few as 100 Candida cells/mL of blood for
all 6 medically important Candida species. In addition to detection
and quantitation, our novel hybridization probe allows the use of
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melting curve analysis to classify positive samples into 2 groups,
antifungal-resistant and antifungal-susceptible. Conclusions: Us-
ing a novel molecular beacon probe, we have developed a pan-
Candida assay that can detect, quantify, and distinguish between
antifungal-resistant and antifungal-susceptible Candida species.
With further clinical validation, we hope that this assay will pro-
vide physicians a rapid means of identifying Candida infection
directly from clinical samples and assist in institution of early
therapy to reduce the hospital stay and high overall costs associated
with management of candidemia.
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Background: Invasive Aspergillosis causes signiﬁcant morbidity
and mortality in bone marrow transplantation recipients. In the
absence of rapid, sensitive, speciﬁc, and quantitative diagnostic
assays, it is estimated that  90% of undiagnosed and untreated
cases result in death. Here we report a rapid, sensitive, and speciﬁc
real time PCR assay to diagnose Aspergillus infections. Methods:
We set out to develop a real-time PCR method to detect and
quantify 8 medically important Aspergillus species (A. fumigatus, A.
clavatus, A. ﬂavus, A. glaucus, A. nidulans, A. niger, A. terreus, and A.
versicolor) in a single assay. We carefully aligned several Aspergillus
multicopy rRNA genes to search for a target that is both speciﬁc
for Aspergillus and conserved for all 8 species. To evaluate the
diagnostic utility of a potential target, we performed real-time
PCR on blood specimens that were spiked with serially diluted
conidia from each of these 8 species. Additionally, we evaluated the
effects of DNA extraction yield on the assay’s sensitivity. For this
purpose, we evaluated 3 commercially available DNA extraction
kits: EZNA, Qiagen, and MagNA Pure DNA extraction methods.
Results: Through sequence analysis, we designed a primer pair
and TaqMan probe speciﬁc for a region of the 18s rRNA gene that
is conserved for all 8 species. On application, our results demon-
strate that this assay can detect and quantify as few as 100 copies of
all 8 medically signiﬁcant Aspergillus conidia per mL of spiked
blood. In evaluating 3 commercially available DNA extraction kits,
we found that the EZNA kit provided the maximum DNA yield
and increased assay sensitivity. Moreover, we determined that
mechanical disruption of the specimen by glass beads resulted in
higher DNA yield and increased assay sensitivity. Conclusion:
Developing a single molecular diagnostic assay for all medically
important Aspergillus species is major challenge. Currently we are
performing both retrospective and prospective studies to evaluate
its diagnostic utility. Recently, the galactomannan-based assay
showed promise in diagnosis of invasive aspergillosis; however, it
still has high false-positivity and false-negativity. Furthermore, an
optimum OD cutoff value has yet to be established for early
diagnosis. Therefore, real-time PCR assay can provide an alterna-
tive means of diagnosis of invasive aspergillosis.
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Background: Hemorrhagic cystitis is a frequent and potentially
serious complication after HSCT. An association between BK
virus in the blood and/or urine and late-onset hemorrhagic cystitis
has been described in literature. The role of BK virus in the
pathogenesis of HC is currently unknown, but it has been sug-
gested by the strong temporal correlation between the onset of
viruria and HC. The goal of this study was to evaluate the rela-
tionship between BK virus load in blood and urine and the severity
of HC after HSCT. Methods: We retrospectively analyzed the
records of 8 patients who had BK virus associated HC after HSCT
seen at our institution between June 2002 and June 2004. All of the
patients were male, with a median age of 45 years (range, 24–61
years). The severity of HC was graded according to the number of
RBCs in the urine: grade 1 (RBCs 50), grade 2 (RBCs 50–100),
grade 3 (RBCs  100), or grade 4 (macroscopic hematuria with/
without clots). Grade 1 and 2 were subdivided into grades 1a/2a
(without symptoms) and 1b/2b (with symptoms of suprapubic pain
and/or dysuria). BK viral load in blood and urine specimens was
measured by a real-time PCR assay done by ViraCor Laboratories.
The Shapiro-Wilks test was used to determine goodness of ﬁt for
normal distributions. The data were found to be nonnormally
distributed, and so correlations were assessed using Spearman’s
test. Results: There was a signiﬁcant correlation between BK viral
load in the urine and the number of RBCs in the urine (P  .0005,
95% conﬁdence interval [CI]  0.1968–0.62550). There was also
a signiﬁcant correlation between BK viral load in the blood and BK
viral load in the urine (P  .0008, 95% CI  0.1807–0.6153).
Conclusion: This study suggests a strong correlation between BK
viruria and the severity of HC, as well as a strong correlation
between BK viruria and BK viremia. More studies are needed to
determine the implications of these correlations on early diagnosis
and treatment of BK viral infection.
LYMPHOMA/MULTIPLE MYELOMA
220
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Background: Salvage of patients with relapsed aggressive non-
Hodgkin’s lymphoma (NHL) before the mid-1990s involved stan-
dard dose chemotherapy (SDC). High-dose chemotherapy (HDC)
combines the same initial drugs as SDC for 2–3 cycles, followed by
high- dose regimes (conditioning) with autologous haemopoietic
stem cell transplantation (AHSCT). In 1995, superior survival for
HDC vs SDC was demonstrated in a European randomized trial
(Philip et al. N Engl J Med 1995;333:1540–5), and HDC rapidly
became the treatment of choice. Because HDC involves substitut-
ing conditioning treatment supported by AHSCT for 3–4 cycles of
SDC, the cost of HDC is higher. The aim of the present study was
to calculate the incremental cost-effectiveness ratio (ICER) for
HDC compared with SDC using Australian costs and the Euro-
pean trial data. Methods: 21 patients transplanted from 1995 to
2002 with characteristics similar to those of the European trial
were identiﬁed from the HDC database of the Newcastle Mater
Hospital (NMH). All drug, transfusion, inpatient and outpatient
attendance, and similar relevant data from start of salvage treat-
ment up to 100 days after conditioning and AHSCT were obtained
and costed. SDC costs required modeling, because all suitable
patients are scheduled to receive HDC if possible, and thus no
concurrent SDC arms exist. SDC cost for 6 cycles of combination
chemotherapy was modeled from data available from the cycles
received before HDC. The European trial survival data were used
because NMH patients were treated only with HDC, patient
numbers were small, and follow-up was short. A lifetime estimate
of patient-years gained by HDC versus SDC was calculated from
the area under survival curves (AUCs) of HDC and SDC from zero
to inﬁnity. Costs and beneﬁts were discounted in advance at 5%
per annum. The ICER was calculated according to the following
formula: incremental cost 
 incremental beneﬁt  (costsHDC 
costsSDC) 
 (AUCHDC  AUCSDC). Results: Costs for HDC and
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